News

/News

Deciphera Releases Positive Trial Results for Ripretinib

Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]

By |2019-08-14T09:38:14-04:00August 14th, 2019|Drug Treatment, News, Research|

Treatment Responses in SDH-deficient GIST – LRG Science

Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry. This study highlights the very unique research role that defines The Life Raft Group.

By |2019-08-21T11:48:56-04:00August 13th, 2019|LRG Science, News, SDH-Deficient GIST|

Blueprint Medicines Announces Next Step for Avaprinitib

Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]

By |2019-08-07T13:24:21-04:00August 7th, 2019|Drug Treatment, News|

Creating Your Personal Cancer Survival Plan

This presentation is best viewed with the "Personal Cancer Survival Plan - 10 Steps to Surviving Cancer Guide" either printed out or opened alongside the video. Open Personal Cancer [...]

By |2019-08-01T11:42:01-04:00July 10th, 2019|GIST Education, GIST Survival Plan, News, Patient Support, Video|

Recent Posts

Upcoming Events

  1. Dr. Sicklick presents an update on Temozolomide Trial
  2. Kathy Sarmiento Medicare 101 Webcast

    LRG Webcast Series: Medicare 101

    September 9 @ 12:00 PM - 1:00 PM